All Clinical Trials

A listing of 292 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Trials

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Healthy Participants Needed (Colonoscopy + Cancer Screening)

Recruiting

Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.

Conditions:

Healthy

Healthy Volunteers

Healthy Subjects

Healthy Volunteer

Healthy Participants

Learn More

Featured Therapy

Unique Treatment for High Blood Pressure

Worried about high blood pressure? Think beyond typical high blood pressure treatments.

People who may be candidates for this procedure:

• Are at least 18 years old
• Have been unable to manage their high blood pressure with medications or lifestyle changes alone¹

Learn about a safe and effective procedure that may help reduce high blood pressure. See if you qualify today.

¹ Kandzari DE, et al. J Am Coll Cardiol. Nov 7, 2023;82(19):1809-1823.

Conditions:

High Blood Pressure

High Blood Pressure (& [Essential Hypertension])

High Blood Pressure (Hypertension).

Hypertension

Essential Hypertension

Learn More

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

Featured Trial

Discover Clinical Trials In Your Area (Compensation Provided)

Recruiting

Clinical trials in your area are actively enrolling — and they compensate you for your time. Finding the right one has never been easier.

- Matched to trials in your zip code
- Compensation for time & travel
- Free or low-cost treatments available
- No experience or medical background needed
- Takes just 30 seconds to see if you qualify

Conditions:

Healthy

Healthy Volunteers

Learn More

Featured Offer

Lose 20% of Body Weight With GLP-1's

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to tirzepatide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).

Get $50 off your first order using promo code: policy-lab-50

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Featured Trial

COVID-19 Vaccine Clinical Trial (Compensation Provided)

Recruiting

Healthy adults ages 50-64 may qualify. You may be eligible if you haven’t received a COVID-19 vaccine and haven’t had COVID-19 in the last 90 days.

Qualified participants may receive compensation for time and travel.

Conditions:

Healthy

Vaccine

COVID19

COVID-19

COVID-19 Vaccine

Learn More

Testing the Safety and Efficacy of the Addition of A New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Etoposide and Cisplatin) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

NCT05019716

Recruiting

This phase I/II trial tests the safety, side effects, and best dose of a new combination of drugs, ZEN003694, cisplatin, and etoposide in treating patients with NUT carcinoma (phase I), and identifies whether this combination therapy works to shrink tumor in these patients (phase II). Another purpose of this study is to see whether there are any changes in patient's tumor or blood characteristics (e.g. genes, molecules, etc.) due to combination therapy. ZEN003694 inhibits the production of certa... Read More

Gender:

ALL

Ages:

12 years and above

Trial Updated:

07/25/2025

Locations: Los Angeles General Medical Center, Los Angeles, California +4 locations

Conditions: Metastatic NUT Carcinoma, Unresectable NUT Carcinoma, Advanced NUT Carcinoma

Learn More ›

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

NCT06926868

Recruiting

The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, and capecitabine) for the treatment of first-line metastatic triple-negative breast cancer (TNBC) or estrogen receptor (ER)-low, human epidermal growth factor receptor 2 (HER2)-negative BC patients who are not candidates... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/24/2025

Locations: Local Institution - 0303, Hot Springs, Arkansas +241 locations

Local Institution - 0303, Hot Springs, Arkansas

Local Institution - 0307, Cerritos, California

Local Institution - 0308, Cerritos, California

Local Institution - 0309, Cerritos, California

Local Institution - 0311, Long Beach, California

Local Institution - 0290, Los Angeles, California

Local Institution - 0283, Los Angeles, California

Local Institution - 0328, Whittier, California

Local Institution - 0289, Aurora, Colorado

Local Institution - 0304, Newark, Delaware

Local Institution - 0282, Miami, Florida

Local Institution - 0296, Pembroke Pines, Florida

Local Institution - 0294, Atlanta, Georgia

Local Institution - 0278, Chicago, Illinois

Local Institution - 0280, Chicago, Illinois

Decatur Memorial Hospital, Decatur, Illinois

Local Institution - 0324, O'Fallon, Illinois

Local Institution - 0286, Covington, Louisiana

Local Institution - 0288, Boston, Massachusetts

Local Institution - 0287, Boston, Massachusetts

Local Institution - 0313, Minneapolis, Minnesota

Local Institution - 0284, Kansas City, Missouri

Local Institution - 0312, New York, New York

Local Institution - 0279, New York, New York

Clinical Research Alliance, Westbury, New York

Local Institution - 0285, White Plains, New York

Local Institution - 0276, Durham, North Carolina

Local Institution - 0316, Eugene, Oregon

Local Institution - 0310, Philadelphia, Pennsylvania

Local Institution - 0281, Greenville, South Carolina

Local Institution - 0315, Austin, Texas

Local Institution - 0314, Houston, Texas

Local Institution - 0305, Tyler, Texas

Local Institution - 0277, Midlothian, Virginia

Local Institution - 0301, Roanoke, Virginia

Local Institution - 0302, Winchester, Virginia

Local Institution - 0345, Buenas Aires, Buenos Aires

Local Institution - 0011, Ciudad autónoma de Buenos Aires, Buenos Aires

Local Institution - 0214, ABB, Ciudad Autónoma De Buenos Aires

Local Institution - 0143, Cordoba, Córdoba

Local Institution - 0137, Río Cuarto, Córdoba

Local Institution - 0142, Rosario, Santa Fe

Local Institution - 0317, Buenos Aires, Not set

Local Institution - 0346, Buenos Aires, Not set

Local Institution - 0012, Ciudad Autónoma de Buenos Aires, Not set

Local Institution - 0035, Brisbane, Queensland

Local Institution - 0197, Ballarat Central, Victoria

Local Institution - 0031, Heidelberg, Victoria

Local Institution - 0274, Melbourne, Victoria

Local Institution - 0028, Subiaco, Western Australia

Local Institution - 0292, Graz, Steiermark

Local Institution - 0268, Innsbruck, Tirol

Local Institution - 0267, Salzburg, Not set

Local Institution - 0270, St. Polten, Not set

Local Institution - 0269, Wien, Not set

Local Institution - 0187, Manaus, Amazonas

Local Institution - 0147, Fortaleza, Ceará

Local Institution - 0157, Vitória, Espírito Santo

Local Institution - 0199, Porto Alegre, Rio Grande Do Sul

Local Institution - 0164, São José do Rio Preto, São Paulo

Local Institution - 0153, Rio de Janeiro, Not set

Local Institution - 0144, São Paulo, Not set

Local Institution - 0149, São Paulo, Not set

Local Institution - 0218, Kelowna, British Columbia

Local Institution - 0217, Victoria, British Columbia

Local Institution - 0265, Ottawa, Ontario

Local Institution - 0215, Montréal, Quebec

Local Institution - 0219, Montréal, Quebec

Local Institution - 0350, Saint-Jerome, Quebec

Local Institution - 0216, Sherbrooke, Quebec

Local Institution - 0138, Santiago, Región Metropolitana De Santiago

Local Institution - 0021, Santiago, Región Metropolitana De Santiago

Local Institution - 0017, Santiago, Región Metropolitana De Santiago

Local Institution - 0018, Santiago, Región Metropolitana De Santiago

Local Institution - 0016, Viña del Mar, Valparaíso

Local Institution - 0195, Medellín, Antioquia

Local Institution - 0201, Rionegro, Antioquia

Local Institution - 0194, Barranquilla, Atlántico

Local Institution - 0182, Puerto Colombia, Atlántico

Local Institution - 0181, Montería, COR

Local Institution - 0327, Bogota, Cundinamarca

Local Institution - 0183, Cali, Valle Del Cauca

Local Institution - 0349, Medellin, Not set

Local Institution - 0089, Bordeaux, Aquitaine

Local Institution - 0272, Dijon, Côte-d'Or

Local Institution - 0098, Toulouse, Haute-Garonne

Local Institution - 0095, Montpellier, Hérault

Local Institution - 0099, Rennes, Ille-et-Vilaine

Local Institution - 0092, Saint Herblain, Loire-Atlantique

Local Institution - 0091, Reims, Marne

Local Institution - 0097, Villejuif, Paris

Local Institution - 0093, Marseille, Provence-Alpes-Côte-d'Azur

Local Institution - 0096, Clermont-Ferrand, Puy-de-Dôme

Local Institution - 0090, Lyon, Rhône-Alpes

Local Institution - 0094, Lille, Not set

Local Institution - 0088, Paris, Not set

Local Institution - 0320, Esslingen, Baden-Württemberg

Local Institution - 0256, Augsburg, Bayern

Local Institution - 0271, München, Bayern

Local Institution - 0306, Frankfurt, Hessen

Local Institution - 0333, Langen, Hessen

Local Institution - 0257, Hannover, Niedersachsen

Local Institution - 0293, Düsseldorf, Nordrhein-Westfalen

Local Institution - 0263, Essen, Nordrhein-Westfalen

Local Institution - 0254, Leipzig, Sachsen

Local Institution - 0255, Lübeck, Schleswig-Holstein

Local Institution - 0261, Berlin, Not set

Local Institution - 0260, Berlin, Not set

Local Institution - 0259, Bonn, Not set

Local Institution - 0258, Dresden, Not set

Local Institution - 0262, Heidelberg, Not set

Local Institution - 0291, Ulm, Not set

Local Institution - 0042, Athens, Attikí

Local Institution - 0038, Athens, Attikí

Local Institution - 0086, Heraklion, Irakleío

Local Institution - 0043, Athens, Not set

Local Institution - 0266, New Delhi, Delhi

Local Institution - 0206, New Delhi, Delhi

Local Institution - 0131, Mumbai, Maharashtra

Local Institution - 0134, Nagpur, Maharashtra

Local Institution - 0125, Chennai, Tamil Nadu

Local Institution - 0130, Hyderabad, Telangana

Local Institution - 0133, Varanasi, Uttar Pradesh

Local Institution - 0352, New Delhi, Not set

Local Institution - 0186, Petah Tikva, HaMerkaz

Local Institution - 0044, Ramat Gan, HaMerkaz

Local Institution - 0048, Hadera, HaTsafon

Local Institution - 0123, Haifa, HaTsafon

Local Institution - 0047, Jerusalem, Yerushalayim

Local Institution - 0051, Napoli, Campania

Local Institution - 0049, Bologna, Emilia-Romagna

Local Institution - 0057, Aviano, Friuli-Venezia Giulia

Local Institution - 0054, Genova, Liguria

Local Institution - 0053, Pontedera, Pisa

Local Institution - 0055, Prato, Toscana

Local Institution - 0052, Milano, Not set

Local Institution - 0058, Napoli, Not set

Local Institution - 0061, Novara, Not set

Local Institution - 0056, Padova, Not set

Local Institution - 0062, Roma, Not set

Local Institution - 0236, Nagoya, Aichi

Local Institution - 0230, Chiba-shi, Chiba

Local Institution - 0240, Matsuyama, Ehime

Local Institution - 0226, Otashi, Gunma

Local Institution - 0222, Sapporo, Hokkaido

Local Institution - 0232, Kanazawa, Ishikawa

Local Institution - 0234, Isehara, Kanagawa

Local Institution - 0237, Yokohama, Kanagawa

Local Institution - 0246, Tsu, Mie

Local Institution - 0223, Sendai-shi, Miyagi

Local Institution - 0238, Suita, Osaka

Local Institution - 0227, Hidaka, Saitama

Local Institution - 0224, Ina-machi, Saitama

Local Institution - 0231, Bunkyo-ku, Tokyo

Local Institution - 0229, Chuo-ku, Tokyo

Local Institution - 0228, Koto, Tokyo

Local Institution - 0245, Shinagawa, Tokyo

Local Institution - 0233, Shinjuku-ku, Tokyo

Local Institution - 0242, Fukuoka, Not set

Local Institution - 0225, Fukushima, Not set

Local Institution - 0243, Hiroshima, Not set

Local Institution - 0244, Kagoshima, Not set

Local Institution - 0235, Kyoto, Not set

Local Institution - 0241, Okayama, Not set

Local Institution - 0239, Osaka, Not set

Local Institution - 0066, Goyang-si, Kyǒnggi-do

Local Institution - 0067, Seongnam, Kyǒnggi-do

Local Institution - 0068, Seoul, Seoul-teukbyeolsi [Seoul]

Local Institution - 0063, Seoul, Seoul-teukbyeolsi [Seoul]

Local Institution - 0071, Seoul, Seoul-teukbyeolsi [Seoul]

Local Institution - 0064, Seoul, Seoul-teukbyeolsi [Seoul]

Local Institution - 0065, Seoul, Seoul-teukbyeolsi [Seoul]

Local Institution - 0069, Daegu, Taegu-Kwangyǒkshi

Local Institution - 0264, Tijuana, Baja California

Local Institution - 0177, Mexico City, DIF

Local Institution - 0329, Mexico City, Distrito Federal

Local Institution - 0178, Guadalajara, Jalisco

Local Institution - 0175, Monterrey, Nuevo León

Local Institution - 0176, Monterrey, Nuevo León

Local Institution - 0173, Oaxaca de Juarez, Oaxaca

Local Institution - 0179, Merida, Yucatán

Local Institution - 0174, Chihuahua, Not set

Local Institution - 0074, Biala Podlaska, Lubelskie

Local Institution - 0072, Warszawa, Mazowieckie

Local Institution - 0220, Warszawa, Mazowieckie

Local Institution - 0076, Opole, Opolskie

Local Institution - 0189, Skórzewo, Wielkopolskie

Local Institution - 0221, Łódź, Łódzkie

Local Institution - 0198, Lisbon, Lisboa

Local Institution - 0106, Lisbon, Lisboa

Local Institution - 0109, Lisbon, Lisboa

Local Institution - 0124, Coimbra, Not set

Local Institution - 0141, Lisboa, Not set

Local Institution - 0111, Porto, Not set

Local Institution - 0253, Porto, Not set

Local Institution - 0212, Bistrita, Bistrița-Năsăud

Local Institution - 0213, Bucharest, București

Local Institution - 0079, Florești, Cluj

Local Institution - 0078, Craiova, Dolj

Local Institution - 0084, Ploiești, Prahova

Local Institution - 0211, Dumbravita, Timiș

Local Institution - 0085, Timișoara, Timiș

Local Institution - 0083, București, Not set

Local Institution - 0077, Cluj, Not set

Local Institution - 0081, Iași, Not set

Local Institution - 0080, Iași, Not set

Local Institution - 0351, East London, Eastern Cape

Local Institution - 0342, Parktown, Gauteng

Local Institution - 0336, Pretoria, Gauteng

Local Institution - 0341, Pretoria, Gauteng

Local Institution - 0340, Soweto, Gauteng

Local Institution - 0105, A Coruña, A Coruña [La Coruña]

Local Institution - 0100, Elche, Alicante

Local Institution - 0102, Barcelona, Barcelona [Barcelona]

Local Institution - 0172, Hospitalet, Barcelona [Barcelona]

Local Institution - 0140, Barcelona, Catalunya [Cataluña]

Local Institution - 0139, San Sebastian, Gipuzkoa

Local Institution - 0104, Madrid, Madrid, Comunidad De

Local Institution - 0108, Madrid, Madrid, Comunidad De

Local Institution - 0101, Malaga, Málaga

Local Institution - 0210, Valencia, Valenciana, Comunitat

Local Institution - 0107, Madrid, Not set

Local Institution - 0103, Sevilla, Not set

Local Institution - 0252, Malmö, Skåne Län [se-12]

Local Institution - 0026, Stockholm, Stockholms Län [se-01]

Local Institution - 0025, Uppsala, Uppsala Län [se-03]

Local Institution - 0024, Örebro, Örebro Län [se-18]

Local Institution - 0247, Linköping, Östergötlands Län [se-05]

Local Institution - 0250, st.Gallen, Sankt Gallen

Local Institution - 0249, Lausanne, Vaud

Local Institution - 0251, Zürich, Not set

Local Institution - 0323, Abu Dhabi, Abū Z̧aby

Local Institution - 0318, Abu Dhabi, Abū Z̧aby

Local Institution - 0322, Al Ain, Abū Z̧aby

Local Institution - 0319, Abu Dhabi, Not set

Local Institution - 0208, Truro, England

Local Institution - 0204, London, London, City Of

Local Institution - 0209, London, London, City Of

Local Institution - 0171, Belfast, Not set

Local Institution - 0004, London, Not set

Local Institution - 0001, Manchester, Not set

Local Institution - 0006, Nottingham, Not set

Conditions: Breast Neoplasms

Learn More ›

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

NCT04301076

Recruiting

This phase I trial studies the side effects and best dose of lenalidomide when given together with usual combination chemotherapy (etoposide, prednisone, vincristine sulfate \[Oncovin\], cyclophosphamide, and doxorubicin hydrochloride \[hydroxydaunorubicin hydrochloride\], or "EPOCH") in treating adult T-cell leukemia-lymphoma. Lenalidomide may help shrink or slow the growth of adult T-cell leukemia-lymphoma. Drugs used in chemotherapy, such as etoposide, vincristine, cyclophosphamide, and doxor... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/24/2025

Locations: Emory University Hospital Midtown, Atlanta, Georgia +18 locations

Conditions: Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma, HTLV-1 Infection

Learn More ›

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

NCT04071223

Recruiting

This phase II trial studies whether adding radium-223 dichloride to the usual treatment, cabozantinib, improves outcomes in patients with renal cell cancer that has spread to the bone. Radioactive drugs such as radium-223 dichloride may directly target radiation to cancer cells and minimize harm to normal cells. Cabozantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving radium-223 dichloride and cabozantinib may help lessen the pain and sympto... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/24/2025

Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +45 locations

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama

UC San Diego Moores Cancer Center, La Jolla, California

University of California Davis Comprehensive Cancer Center, Sacramento, California

Rush University Medical Center, Chicago, Illinois

University of Chicago Comprehensive Cancer Center, Chicago, Illinois

Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois

Loyola University Medical Center, Maywood, Illinois

UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois

University of Chicago Medicine-Orland Park, Orland Park, Illinois

UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny, Iowa

Iowa Methodist Medical Center, Des Moines, Iowa

UI Health Care Mission Cancer and Blood - Des Moines Clinic, Des Moines, Iowa

University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa

University of Kansas Cancer Center, Kansas City, Kansas

University of Kansas Cancer Center-Overland Park, Overland Park, Kansas

University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas

East Jefferson General Hospital, Metairie, Louisiana

LSU Healthcare Network / Metairie Multi-Specialty Clinic, Metairie, Louisiana

Tulane University School of Medicine, New Orleans, Louisiana

Dana-Farber Cancer Institute, Boston, Massachusetts

UMass Memorial Medical Center - University Campus, Worcester, Massachusetts

Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor, Michigan

Henry Ford Hospital, Detroit, Michigan

Trinity Health Saint Mary Mercy Livonia Hospital, Livonia, Michigan

Minnesota Oncology - Burnsville, Burnsville, Minnesota

Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota

Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri

University of Kansas Cancer Center - North, Kansas City, Missouri

University of Kansas Cancer Center - Lee's Summit, Lee's Summit, Missouri

Washington University School of Medicine, Saint Louis, Missouri

Siteman Cancer Center-South County, Saint Louis, Missouri

Missouri Baptist Medical Center, Saint Louis, Missouri

Siteman Cancer Center at Saint Peters Hospital, Saint Peters, Missouri

NYP/Weill Cornell Medical Center, New York, New York

UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

Duke University Medical Center, Durham, North Carolina

Ohio State University Comprehensive Cancer Center, Columbus, Ohio

University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

UPMC-Shadyside Hospital, Pittsburgh, Pennsylvania

UT Southwestern Simmons Cancer Center - RedBird, Dallas, Texas

UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas

UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth, Texas

UT Southwestern Clinical Center at Richardson/Plano, Richardson, Texas

Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah

Medical College of Wisconsin, Milwaukee, Wisconsin

Conditions: Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Collecting Duct Carcinoma, Kidney Medullary Carcinoma, Metastatic Malignant Neoplasm in the Bone, Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8, Unclassified Renal Cell Carcinoma

Learn More ›

Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea

NCT00695214

Recruiting

Prospective, interventional cohort study of drug-induced sleep endoscopy (DISE) to evaluate the upper airway in a cohort of obstructive sleep apnea (OSA) surgical patients. This study has investigated the reliability of this technique, demonstrating moderate-substantial interrater and test-retest reliability. This research has also compared DISE findings to those of the lateral cephalogram X-ray and examined DISE findings in individuals who have not responded to previous sleep apnea surgery. The... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/24/2025

Locations: UCLA Santa Monica Medical Center, Santa Monica, California

Conditions: Sleep Apnea, Obstructive

Learn More ›

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

NCT04172532

Recruiting

This phase I/II trial studies the safety, side effects and best dose of M3814 and to see how well it works when given together with radiation therapy in treating patients with pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced). M3814 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/24/2025

Locations: City of Hope Comprehensive Cancer Center, Duarte, California +41 locations

City of Hope Comprehensive Cancer Center, Duarte, California

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California

City of Hope at Irvine Lennar, Irvine, California

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California

University of California Davis Comprehensive Cancer Center, Sacramento, California

UCHealth University of Colorado Hospital, Aurora, Colorado

Sibley Memorial Hospital, Washington, District of Columbia

Northwestern University, Chicago, Illinois

University of Kansas Clinical Research Center, Fairway, Kansas

HaysMed, Hays, Kansas

University of Kansas Cancer Center, Kansas City, Kansas

Lawrence Memorial Hospital, Lawrence, Kansas

The University of Kansas Cancer Center - Olathe, Olathe, Kansas

University of Kansas Cancer Center-Overland Park, Overland Park, Kansas

Mercy Hospital Pittsburg, Pittsburg, Kansas

Salina Regional Health Center, Salina, Kansas

University of Kansas Health System Saint Francis Campus, Topeka, Kansas

University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas

University of Kentucky/Markey Cancer Center, Lexington, Kentucky

Wayne State University/Karmanos Cancer Institute, Detroit, Michigan

Weisberg Cancer Treatment Center, Farmington Hills, Michigan

University Health Truman Medical Center, Kansas City, Missouri

University of Kansas Cancer Center - North, Kansas City, Missouri

University of Kansas Cancer Center - Lee's Summit, Lee's Summit, Missouri

University of Kansas Cancer Center at North Kansas City Hospital, North Kansas City, Missouri

Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire

Saint Barnabas Medical Center, Livingston, New Jersey

Monmouth Medical Center, Long Branch, New Jersey

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

Montefiore Medical Center-Einstein Campus, Bronx, New York

Montefiore Medical Center - Moses Campus, Bronx, New York

Roswell Park Cancer Institute, Buffalo, New York

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York

Mount Sinai Hospital, New York, New York

NYP/Weill Cornell Medical Center, New York, New York

Wake Forest University at Clemmons, Clemmons, North Carolina

Wake Forest Baptist Health - Wilkes Medical Center, Wilkesboro, North Carolina

Wake Forest University Health Sciences, Winston-Salem, North Carolina

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee

Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah

Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia

Conditions: Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8

Learn More ›

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

NCT05422794

Recruiting

This phase Ib trial tests the safety and tolerability of ZEN003694 in combination with an immunotherapy drug called pembrolizumab and the usual chemotherapy approach with nab-paclitaxel for the treatment of patients with triple negative-negative breast cancer that has spread to other parts of the body (advanced). Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Nab-paclitaxel is an albumin-stabilized nanopar... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/23/2025

Locations: Boston Medical Center, Boston, Massachusetts +4 locations

Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Triple-Negative Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma

Learn More ›

A Study to Investigate the Safety, Tolerability, and Drug Levels of BMS-986419 (Part 1) and the Effects Multiple Doses of BMS-986419 on Cardiac Repolarization (Part 2) in Healthy Participants

NCT06846866

Recruiting

The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics of BMS-986419 (Part 1) and the effects of multiple doses of BMS-986419 on cardiac repolarization (Part 2) in healthy participants.

Gender:

ALL

Ages:

Between 18 years and 55 years

Trial Updated:

07/22/2025

Locations: Celerion, Tempe, Arizona

Conditions: Healthy Volunteers

Learn More ›

Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.

NCT05609630

Recruiting

Juvenile Idiopathic Arthritis (JIA) is the most common type of arthritis that affects children. The term "idiopathic" means "of unknown origin". It is a chronic (long-lasting) disease that causes swelling, warmth, and pain of one or more small joints. Systemic JIA ia a rare and serious form of JIA. Systemic" means it may affect not only the joints but other parts of the body, including the liver, lungs and heart. sJIA is more severe and can be more challenging to diagnose and treat than other ty... Read More

Gender:

ALL

Ages:

Between 1 year and 17 years

Trial Updated:

07/22/2025

Locations: Phoenix Children's Hospital /ID# 253403, Phoenix, Arizona +41 locations

Phoenix Children's Hospital /ID# 253403, Phoenix, Arizona

New York Medical College /ID# 253437, Valhalla, New York

Levine Children's Hospital /ID# 253491, Charlotte, North Carolina

Cincinnati Childrens Hospital Medical Center /ID# 251827, Cincinnati, Ohio

Randall Children's Hospital /ID# 251829, Portland, Oregon

Instituto CAICI S.R.L /ID# 251448, Rosario, Santa Fe

Centro de Investigaciones Medicas Tucuman /ID# 251781, San Miguel de Tucuman, Tucuman

Monash Health - Monash Medical Centre /ID# 251691, Clayton, Victoria

Royal Children's Hospital /ID# 251663, Parkville, Victoria

Landeskrankenhaus Bregenz /ID# 266317, Bregenz, Vorarlberg

CMiP - Centro Mineiro de Pesquisa Ltda - ME /ID# 251769, Juiz de Fora, Minas Gerais

Hospital Sao Paulo /ID# 251765, Sao Paulo, Not set

Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao /ID# 251764, Sao Paulo, Not set

The Children's Hospital of Chongqing Medical University /ID# 251539, Chongqing, Chongqing

Children'S Hospital Of Soochow University /ID# 251755, Suzhou, Jiangsu

Xi'an Children's Hospital /ID# 251693, Xi'an, Shaanxi

Children's Hospital of Fudan University /ID# 251619, Shanghai, Shanghai

The Children's Hospital of Zhejiang University School of Medicine /ID# 251754, Hangzhou, Zhejiang

Universitaetsklinikum Freiburg /ID# 253288, Freiburg, Baden-Wuerttemberg

Asklepios Klinik Sankt Augustin /ID# 251565, Sankt Augustin, Nordrhein-Westfalen

St. Josef-Stift Sendenhorst /ID# 268680, Sendenhorst, Nordrhein-Westfalen

Hamburger Zentrum fuer Kinder- und Jugendrheumatologie /ID# 251564, Hamburg, Not set

Semmelweis Egyetem /ID# 266750, Budapest, Not set

Azienda Ospedaliero Universitaria Meyer /ID# 251775, Florence, Firenze

IRCCS Istituto Giannina Gaslini /ID# 251776, Genoa, Genova

Hyogo Prefectural Kobe Children's Hospital /ID# 251649, Kobe-shi, Hyogo

St Marianna University School Of Medicine /ID# 251623, Kawasaki-shi, Kanagawa

Niigata University Medical & Dental Hospital /ID# 251538, Niigata-shi, Niigata

Osaka Medical and Pharmaceutical University Hospital /ID# 252092, Takatsuki-shi, Osaka

Institute of Science Tokyo Hospital /ID# 251505, Bunkyo-ku, Tokyo

CREA de Guadalajara SC /ID# 252917, Guadalajara, Jalisco

Universitair Medisch Centrum Utrecht /ID# 267435, Utrecht, Not set

Hospital Sant Joan de Deu /ID# 251353, Esplugues de Llobregat, Barcelona

Hospital Universitario y Politecnico La Fe /ID# 251352, Valencia, Not set

Queen Silvia Children's Hosp /ID# 251318, Gothenburg, Vastra Gotalands Lan

National Taiwan University Hospital /ID# 267387, Taipei City, Taipei

Linkou Chang Gung Memorial Hospital /ID# 267390, Taoyuan City, Not set

Gazi University Medical Faculty /ID# 253677, Ankara, Not set

Istanbul University Istanbul Medical Faculty /ID# 251652, Istanbul, Not set

Istanbul Universitesi-Cerrahpasa Cerrahpasa Tip Fakultesi /ID# 251651, Istanbul, Not set

Umraniye Training and Res Hosp /ID# 251653, Istanbul, Not set

Great Ormond Street Children's Hospital /ID# 251512, London, Greater London

Conditions: Juvenile Idiopathic Arthritis

Learn More ›

Advancing Access to HIV/HCV Testing for People Who Inject Drugs (PWID)

NCT06730555

Recruiting

The purpose of this study is to test the effectiveness of the ACCESS strategy: an organizational-level intervention that uses funding and practice facilitation to improve the organizational capacity of syringe services programs (SSPs) to implement routine, opt-out HIV and Hepatitis C (HCV) testing and linkage to care for people who inject drugs (PWID).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/21/2025

Locations: University of Miami, Miami, Florida

Conditions: HIV Infections

Learn More ›

Functional Near-Infrared Spectroscopy and Virtual Reality Relaxation Programs for Pain Management in Patients With Cancer

NCT06456411

Recruiting

This study attempts to measure pain severity, location of pain, and feasibility in patients with cancer using functional near-infrared spectroscopy and virtual reality relaxation programs. Functional near-infrared spectroscopy and virtual reality relaxation programs may help relieve pain in patients with cancer who are receiving treatment.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/17/2025

Locations: Roswell Park Cancer Institute, Buffalo, New York

Conditions: Breast Carcinoma, Kidney Carcinoma, Malignant Solid Neoplasm, Malignant Thoracic Neoplasm

Learn More ›

A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants

NCT06673238

Recruiting

This is a Phase 1, first-in-human study to investigate safety, tolerability, and pharmacokinetics of ABBV-722 after oral dosing in healthy adult participants.

Gender:

ALL

Ages:

Between 18 years and 65 years

Trial Updated:

07/17/2025

Locations: Acpru /Id# 270279, Grayslake, Illinois

Conditions: Healthy Volunteer

Learn More ›